Screener
Rigel Pharmaceuticals RIGL Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Rigel Pharmaceuticals’s 10-K, filed March 3, 2026.
- Filed
- Mar 3, 2026, 4:06 PM EST
- Fiscal year
- FY2025
- Accession
- 0001034842-26-000015
| Line item | As of December 31, 2025 | As of December 31, 2024 |
|---|---|---|
| Commitments | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of December 31, 2025 and 2024 | — | — |
| Common stock, $0.001 par value; 400,000,000 shares authorized; 18,310,934 and 17,710,216 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 18 | 18 |
| Additional paid-in capital | 1,414,322 | 1,393,325 |
| Accumulated other comprehensive income | 181 | 10 |
| Accumulated deficit | (1,023,041) | (1,390,065) |
| Total stockholders’ equity | 391,480 | 3,288 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Rigel Pharmaceuticals's common stock, par value (in dollars per share)?
- Rigel Pharmaceuticals (RIGL) reported common stock, par value (in dollars per share) of $0 in Q4 2025.
Ask your AI about Rigel Pharmaceuticals's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude